Pharmasset to Present at Two Upcoming Investor Conferences.
PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. announces management will present at the Rodman and Renshaw 10th Annual Global Investment Conference and the Lazard Capital Markets 5th Annual Healthcare Conference. Both conferences will be held in New York, NY. Schaefer Price, Pharmasset's President and Chief Executive...

Adults and shots: they're not just for tots.
Adults, listen up: Vaccines aren't just for kids. The shots you received as a child won't protect you forever. Whether you reached adulthood this year or decades ago, your need for vaccines never ends. According to the Centers for Disease Control and Prevention, there are vaccines available to protect...

Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections.
PARIS, November 12 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines Novexel's broad spectrum beta-lactamase inhibitor, NXL104, with the well established...

Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial.
SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Vical Incorporated announced today that the company has completed enrollment of subjects in a Phase 2 trial of its therapeutic DNA vaccine designed to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell transplant recipients. An interim analysis of immunogenicity data for...

New Research Shows Specific Antioxidant, Found in Cherries, May Boost the Body's Defenses Against the Flu.
Study Links Quercetin To Reduced Risk for Respiratory Infection LANSING, Mich., Nov. 12 /PRNewswire/ -- For those looking for a natural way to stay well this cold and flu season, there's yet another reason to choose cherries, one of today's hottest "Super Fruits." In conjunction with the...

A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks.
BOSTON, Nov. 12 /PRNewswire/ -- WHO and CDC have stated that the predictive accuracy of their annual formulations for human influenza vaccines is "suboptimal" -- often correct less than 50% of the time, especially for seniors. Perhaps in part because we are not yet accurate in our predictions of...

LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates.
LINCOLN, Neb., Nov. 12 /PRNewswire/ -- Protease substrates provide a sensitive method to detect protease activity, measure potency of inhibitors and screen compound collections for discovery of drug candidates. LI-COR Biosciences now offers three different IRDye NIR-FRET Protease Substrates: IRDye 800CW/QC-1 HIV-1, IRDye 800CW/QC-1 BACE, and IRDye 800CW/QC-1 CSP-3....

Bacteriophages may function as novel antimicrobials.
It appears that some foodborne bacteria may be overstaying their welcome in products after bacteriophages take up residence inside them and replicate. The progeny of these bacteriophages literally kill their bacterial hosts on their way out the cellular door. Bacteriophages are environmentally ubiquitous and only attack bacteria....

GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
LONDON, Nov. 12 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that Gemstone Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Genelabs Technologies, Inc. , for $1.30 in cash without interest and less any required withholding...

Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting.
CALGARY, Oct. 23 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today announced that an abstract entitled "Phase I Trial of Oncolytic Reovirus (REOLYSIN(R)) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers" will be available in the November/December issue of the Journal of Immunotherapy, the official...